ABCL - CIK 0001703057
AbCellera Biologics Inc. trades as ABCL and has a market capitalization of $1.57 B, making it the #2295 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $75.13M, up 160.6% from the prior year and net income of -$146.41M. This page tracks AbCellera Biologics Inc. through 297 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years AbCellera Biologics Inc.'s revenue grew from $11.61M to $75.13M, a compound annual growth rate of 36.5%. Net profit margin compressed from -19.0% to -194.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Insider trade | 4 | 2026-03-02 |
The largest companies sharing AbCellera Biologics Inc.'s SEC industry classification (pharmaceutical preparations).
AbCellera Biologics Inc. (ABCL) has a market capitalization of $1.57 B as of 2026-06-10, ranking #2295 among US-listed companies.
AbCellera Biologics Inc. reported revenue of $75.13M for fiscal year 2025, an increase of 160.6% year over year.
In its latest fiscal year AbCellera Biologics Inc. reported a net loss of $146.41M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.